Sana Biotechnology, Inc. (SANA)

NASDAQ: SANA · IEX Real-Time Price · USD
6.00
-0.25 (-4.00%)
Sep 30, 2022 4:00 PM EDT - Market closed
-4.00%
Market Cap 1.14B
Revenue (ttm) n/a
Net Income (ttm) -297.91M
Shares Out 190.23M
EPS (ttm) -1.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,686,814
Open 5.55
Previous Close 6.25
Day's Range 5.51 - 6.18
52-Week Range 3.93 - 23.50
Beta n/a
Analysts Buy
Price Target 13.60 (+126.7%)
Earnings Date Nov 7, 2022

About SANA

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the tr... [Read more...]

Industry Biotechnology
IPO Date Feb 4, 2021
Employees 461
Stock Exchange NASDAQ
Ticker Symbol SANA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SANA stock is "Buy." The 12-month stock price forecast is 13.6, which is an increase of 126.67% from the latest price.

Price Target
$13.6
(126.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

7 Unknown Biotech Stocks That Could Rocket in 2023

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

1 week ago - InvestorPlace

Sana Biotechnology to Present at September 2022 Investor Conferences

SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its ...

3 weeks ago - GlobeNewsWire

7 Stocks Due for a Stunning Short Squeeze

Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-sque...

Other symbols: LMNDMVISSIENSTOKTTCFWE
1 month ago - InvestorPlace

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derive...

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppre...

3 months ago - GlobeNewsWire

Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including i...

New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented New data highlighting the potential of human islet cell transplantation for type 1 diabetes ...

3 months ago - GlobeNewsWire

Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its p...

3 months ago - GlobeNewsWire

Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel f...

SAN FRANCISCO and SUZHOU, China , June 5, 2022  /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...

3 months ago - PRNewsWire

Sana Biotechnology to build manufacturing in Seattle area, switching from California

After announcing plans last summer to build its manufacturing facility in California, Sana Biotechnology has changed course.

4 months ago - GeekWire

Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additiona...

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice Presid...

4 months ago - GlobeNewsWire

Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates

Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT

4 months ago - GlobeNewsWire

Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference

SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its pr...

4 months ago - GlobeNewsWire

Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy...

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts coverin...

5 months ago - GlobeNewsWire

Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

Plans to present data at multiple scientific conferences in 2022

6 months ago - GlobeNewsWire

Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference

SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its ...

6 months ago - GlobeNewsWire

Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 Americ...

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data fro...

6 months ago - GlobeNewsWire

Biotech IPOs Have Slowed to a Snail's Pace

Sana Biotechnology Inc. ( SANA , Financial) and Lyel Immunopharma Inc. ( LYEL , Financial) are poster children for what's happening in the biotech initial public offering market. The two companies raise...

Other symbols: LYEL
7 months ago - GuruFocus

3 Biotechs That Will Soar Regardless of COVID-19

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

Other symbols: PIRSTXG
8 months ago - The Motley Fool

Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies

Sana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics. The construc...

8 months ago - Benzinga

Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

License will enable Sana's in vivo and ex vivo engineered T cell programs for B cell malignancies

8 months ago - GlobeNewsWire

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinica...

Agreement combines IASO Bio and Innovent's CAR construct, validated in clinical trials, with Sana's in vivo and ex vivo engineered cell therapy programs Agreement combines IASO Bio and Innovent's CAR co...

8 months ago - GlobeNewsWire

Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its p...

8 months ago - GlobeNewsWire

Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs

Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells

9 months ago - GlobeNewsWire

Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presente...

10 months ago - GlobeNewsWire

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy prog...

Other symbols: BEAM
11 months ago - Benzinga

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

Sana Biotechnology has a new $50 million tool in its toolbox.

11 months ago - GeekWire